ATXI (Avenue Therapeutics) Short Interest


ATXI Avenue Therapeutics Inc ATXI
31 GF Score
Price $0.32
! 1 Warning Sign
View Full Analysis

What is Avenue Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ATXI vs PTIX, EVFM, AGTX: Short Interest Comparison

For the Biotechnology subindustry, Avenue Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avenue Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avenue Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Avenue Therapeutics's Short Interest falls into.


ATXI
31GF Score
Avenue Therapeutics Inc ATXI
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avenue Therapeutics Business Description

Address 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL, USA, 33154
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It is focused on advancing impactful therapies with the potential to overcome limitations of existing treatment options and ultimately transform patient outcomes. Current product candidates include ATX-04, a selective beta adrenergic agonist for Pompe disease, intravenous tramadol (IV tramadol), a Schedule IV opioid for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. The company operates in one reportable segment, the development and commercialization of therapies for the treatment of neurologic diseases.
31GF Score

Get the complete analysis for ATXI

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.32
Price